Investigating the Role of Dahuang in Hepatoma Treatment Using Network Pharmacology, Molecular Docking, and Survival Analysis.

Abstract

Hepatoma is one of the most common malignant tumors. The incidence rate is high in developing countries, and China has the most significant number of cases. Dahuang is a classic traditional antitumor drug commonly used in China and has also been applied to treat hepatoma. However, the potential mechanism of Dahuang in treating hepatoma is not clear. Therefore, this study is aimed at elucidating the possible molecular mechanism and key targets of Dahuang using methods of network pharmacology, molecular docking, and survival analysis. Firstly, the active ingredients and key targets of Dahuang were analyzed through public databases, and then the drug-ingredient-target-disease network diagram of Dahuang against hepatoma was constructed. Five main active components and five core targets were determined according to the enrichment degree. Enrichment analysis demonstrated that Dahuang treated hepatoma through the multiple pathways in cancer. Additionally, molecular docking predicted that aloe-emodin and PIK3CG depicted the best binding energy. Survival analysis indicated that a high/ESR1 gene expression had a relatively good prognosis for patients with hepatoma (p < 0.05). In conclusion, the current study results demonstrated that Dahuang could treat hepatoma through a variety of active ingredients, targets, and multiantitumor pathways. Moreover, it effectively improved the prognosis of hepatoma patients. ESR1 is the potential key gene that is beneficial for the survival of hepatoma patients. Also, aloe-emodin and beta-sitosterol are the two main active crucial ingredients for hepatoma treatment. The study also provided some functional bases and references for the development of new drugs, target mining, and experimental animal research of hepatoma in the future.

• Authors: Bin Yu, Maoru Wang, Hui Xu, Rongrong Gao, Yuanying Zhu, Hong Ning, Xiaoyu Dai
• Journal: BioMed research international (Biomed Res Int) Vol. 2022 Pg. 5975223 ( 2022) ISSN: 2314-6141 [Electronic] United States
• PMID: 35872841 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 Bin Yu et al.

Chemical References

• Drugs, Chinese Herbal
• Emodin

Topics

• Carcinoma, Hepatocellular (drug therapy, genetics)
• Drugs, Chinese Herbal (chemistry, pharmacology, therapeutic use)
• Emodin
• Humans
• Liver Neoplasms (drug therapy, genetics)
• Medicine, Chinese Traditional
• Molecular Docking Simulation
• Network Pharmacology
• Survival Analysis